



## DNAtrix wins \$2 million FDA grant for cancer immunotherapy

DNAtrix, a Houston based biotech company, has won a \$2 million grant from the Food and Drug Administration to support clinical trials of a virus-driven immunotherapy for cancer.

The company is evaluating its DNX-2401 product, a modified version of the common cold virus that targets and kills cancer cells in the body. The grant funds will support Phase 2 trials of the mutated virus.

“We are delighted by the FDA's continued recognition of DNX-2401 as a promising treatment for glioblastoma by awarding this grant to further support our product development strategy,” said Frank Tufaro, DNAtrix CEO. “This is an important accomplishment for the company and another significant step toward bringing DNX-2401 to patients with devastating brain tumors.”

### **About DNAtrix Inc.**

As a clinical-stage company developing modified oncolytic viruses for the treatment of the most aggressive forms of cancer, DNAtrix is a privately held company headquartered in Houston, Texas. For more information, please visit the company website at <http://www.dnatrx.com>.

Source: <http://www.chron.com/local/prognosis/article/DNAtrix-clinical-stage-biotech-company-awarded-9123087.php>

August 4th 2016